Scarica l'app Stockscreener
26.21
1.51%
-0.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$26.63
Aprire:
$26.59
Volume 24 ore:
257.31K
Relative Volume:
0.34
Capitalizzazione di mercato:
$1.51B
Reddito:
$681.88M
Utile/perdita netta:
$122.63M
Rapporto P/E:
12.42
EPS:
2.11
Flusso di cassa netto:
$220.18M
1 W Prestazione:
-2.06%
1M Prestazione:
-18.78%
6M Prestazione:
-6.13%
1 anno Prestazione:
-24.72%
Intervallo 1D:
$26.18
$26.97
Intervallo di 1 settimana:
$25.95
$26.97
Portata 52W:
$25.95
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Confronta HRMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
26.21 | 1.54B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.58 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
484.65 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.00 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.09 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.82 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
UBS Maintains HRMY Rating, Lowers Price Target to $43.00 | HRMY Stock News - GuruFocus
What Wall Street predicts for Harmony Biosciences Holdings Inc. stock priceEntry Point & Daily Oversold Bounce Ideas - newser.com
UBS lowers Harmony Biosciences stock price target to $43 on competitive pressure - Investing.com
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $43 at UBS - StreetInsider
Published on: 2025-10-14 23:52:13 - newser.com
Long term hold vs stop loss in Harmony Biosciences Holdings Inc.2025 Geopolitical Influence & Daily Chart Pattern Signals - newser.com
Harmony Biosciences Holdings (HRMY) Stock Analysis: Unveiling a Potential 69% Upside for Investors - DirectorsTalk Interviews
Harmony Biosciences Holdings Inc. stock trend outlook and recovery pathWeekly Trend Recap & Smart Money Movement Tracker - newser.com
Custom watchlist performance reports with Harmony Biosciences Holdings Inc.2025 Market Sentiment & AI Optimized Trade Strategies - newser.com
Published on: 2025-10-13 07:02:21 - newser.com
Harmony Biosciences Hits 52-Week Low at $26.15 Amid Market Turbulence - Markets Mojo
Harmony Biosciences Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Harmony Biosciences (NASDAQ:HRMY) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Harmony Biosciences Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Does Harmony Biosciences Holdings Inc. show high probability of reboundGlobal Markets & Technical Buy Zone Confirmations - newser.com
Can Harmony Biosciences Holdings Inc. hit a new high this monthJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Using AI based signals to follow Harmony Biosciences Holdings Inc.July 2025 News Drivers & Daily Technical Forecast Reports - newser.com
Harmony Biosciences stock hits 52-week low at $26.26 By Investing.com - Investing.com Nigeria
What analysts say about Harmony Biosciences Holdings Inc stockEarnings Volatility Patterns & Amplify Gains With Picks - earlytimes.in
Harmony Biosciences (NASDAQ:HRMY) Hits New 1-Year LowWhat's Next? - MarketBeat
Harmony Biosciences stock hits 52-week low at $26.26 - Investing.com India
Robeco Institutional Asset Management B.V. Takes $1.48 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Sahm
Is Harmony Biosciences (HRMY) the Oversold Biotech Stock to Buy Now? - MSN
Using Bollinger Bands to evaluate Harmony Biosciences Holdings Inc.Weekly Trade Report & Weekly Breakout Watchlists - newser.com
Understanding Harmony Biosciences Holdings Inc.’s price movementOil Prices & Low Drawdown Investment Strategies - newser.com
What drives Harmony Biosciences Holdings Inc stock priceSector Leadership Analysis & Master Stock Selection - earlytimes.in
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights - MyChesCo
Exit strategy if you’re trapped in Harmony Biosciences Holdings Inc.July 2025 Trends & Stock Portfolio Risk Management - newser.com
Harmony Biosciences Hits New 52-Week Low at $26.26 - Markets Mojo
Harmony Biosciences (HRMY): Assessing Valuation After RECONNECT Trial Disappointment for ZYN002 in Fragile X Syndrome - Yahoo Finance
H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback - MSN
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates - MSN
10 Best Low Priced Growth Stocks to Buy Now - Insider Monkey
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of “Buy” from Analysts - Defense World
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Harmony Biosciences Holdings Inc Azioni (HRMY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kapadia Sandip | CHIEF FINANCIAL OFFICER |
Aug 15 '25 |
Sale |
36.50 |
21,573 |
787,378 |
0 |
3.93%
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):